Lung cancers treated by Tomotherapy represent between 60 and 100 patients per year at the CHR of Metz-Thionville. Some patients were observed to present acute toxicities during treatment such as dysphagia or esophagitis of CTCAE grade \> 2. Beyond well known therapeutic and comorbidities factors, the pathophysiology of these events is largely ruled by a constitutional factor - the enzymatic equipment allowing more or less good repair of the DNA lesions induced by radiotherapy (RT). This equipment is characteristic of each individual, hence the term individual radiosensitivity (IR).The scientific literature is rather poor in data describing the frequency of these toxicities in patients receiving RT for lung cancer. The objective of this study is to describe the frequency of acute and late toxicities after normofractionated radiotherapy of 66 Gy in 33 fractions in patients with small cell or non-small cell lung cancer, stage 2 or 3.
Study Type
OBSERVATIONAL
Enrollment
318
CHR Metz-Thionville/Hopital de Mercy
Metz, France
late toxicity of radiotherapy
according to CTCAE v5.0 grading
Time frame: up to 2 years after tomotherapy treatment
acute toxicity of radiotherapy
according to CTCAE v5.0 grading
Time frame: 6 months following tomotherapy treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.